Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 12 · below the Ichimoku cloud · RSI 34 · MACD below its signal
None of the 29 investors followed here reported a position in CERO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CERO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 30, 2025 | Atwood Brian GDirector | Conversion of Exercise of derivative security at price 0.00 per share. | 294.5K | $29 |
| Dec 12, 2024 | Yk Bioventures Opportunities Gp I, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.06 - 0.08 per share. | 5.96M | $400.46K |
| Dec 9, 2024 | Yk Bioventures Opportunities Gp I, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 0.09 - 0.12 per share. | 3.66M | $383.37K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -28.4 | -27.1 | 0.0 | -8.6 | -43.8 | -38.9 | -9.1 | 30.0 | -15.4 | -36.4 | −89.6% | ||
| 2025 | -64.3 | -22.0 | -56.3 | 21.9 | -50.0 | 8.2 | -19.4 | -3.1 | -32.3 | -98.6 | 19.7 | -21.2 | −99.9% |
| 2024 | 0.1 | -73.2 | 3.9 | -54.7 | -33.1 | -67.8 | -47.8 | -18.6 | -26.8 | -7.5 | 124.4 | -68.9 | −99.5% |
| 2023 | 2.4 | 0.1 | 1.4 | 3.5 | -2.3 | 0.9 | -1.1 | 0.3 | 0.5 | 0.1 | 0.0 | 1.2 | +7.1% |
| 2022 | 0.1 | 0.3 | 0.6 | 0.1 | 0.1 | -0.1 | 0.4 | 0.1 | 0.2 | 0.8 | 0.7 | 0.3 | +3.6% |
| 2021 | -0.2 | −0.2% |
No analyst coverage for this instrument.
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.